In Support of Universal Admission Testing for SARS-CoV-2 During Significant Community Transmission.
Chanu RheeMichael KlompasTheodore R PakJulia R KöhlerPublished in: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2023)
Many hospitals have stopped or are considering stopping universal admission testing for SARS-CoV-2. We discuss reasons why admission testing should still be part of a layered system to prevent hospital-acquired SARS-CoV-2 infections during times of significant community transmission. These include the morbidity of SARS-CoV-2 in vulnerable patients, the predominant contribution of presymptomatic and asymptomatic people to transmission, the high rate of transmission between patients in shared rooms, and data suggesting surveillance testing is associated with fewer nosocomial infections. Preferences of diverse patient populations, particularly the hardest hit communities, should be surveyed and used to inform prevention measures. Hospitals' ethical responsibility to protect patients from serious infections should predominate over concerns about costs, labor, and inconvenience. We call for more rigorous data on the incidence and morbidity of nosocomial SARS-CoV-2 infections and more research to help determine when to start, stop, and restart universal admission testing and other prevention measures.
Keyphrases
- sars cov
- end stage renal disease
- healthcare
- ejection fraction
- chronic kidney disease
- newly diagnosed
- emergency department
- respiratory syndrome coronavirus
- prognostic factors
- peritoneal dialysis
- public health
- escherichia coli
- electronic health record
- coronavirus disease
- risk factors
- deep learning
- acinetobacter baumannii
- highly efficient